GARCIA LOPEZ MONICA,TORRENS JOVER ANTONI,DIAZ FERNANDEZ JOSE LUIS,CAAMANO MOURE ANA MARIA
申请号：
NZ60353211
公开号：
NZ603532A
申请日:
2011.05.26
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
The disclosure refers to compounds of general formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved. The disease may be: diarrhea lipoprotein disorders migraine obesity elevated triglyceride levels chylomicronemia dysbetalipoproteinemia hyperlipoproteinemia hyperlipidemia mixed hyperlipidemia hypercholesterolemia hypertriglyceridemia sporadic hypertriglyceridemia inherited hypertriglyceridemia dysbetalipoproteinemia arthritis hypertension arrhythmia ulcer learning, memory and attention deficits cognition disorders neurodegenerative diseases demyelinating diseases addiction to drugs and chemical substances including cocaine, amphetamine, ethanol and nicotine tardive dyskinesia ischemic stroke epilepsy stroke stress cancer psychotic conditions inflammation autoimmune diseases depression, anxiety, schizophrenia or pain. Compounds of the disclosure include: 1-(4-(2-((1-(3,4-dichlorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one, 4-(2-((1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)morpholine, 1-(4-(3-((1-cyclohexyl-5-methyl-1H-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone, and 4-(2-((5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yl)methoxy)ethyl)morpholine.
